Cell-based assays for drug discovery: Types, applications, and how to choose
Introduction: why cell-based assays are central to modern drug discovery
Over the past two decades, screening strategies have moved beyond target-isolated biochemical readouts toward cell-based assays for drug discovery. These assays preserve signaling networks, membrane context, pathway crosstalk, and phenotype-level responses. Biochemical assays still remain valuable for potency ranking, enzyme kinetics, and direct target engagement, but many discovery questions now require intact biology. Cellular systems can reveal whether a compound enters relevant cells, engages its target in a native environment, shifts downstream signaling, modifies disease-relevant behavior, or produces early signs of toxicity. This added context makes cell-based formats central to mechanism-of-action studies, lead optimization, translational pharmacology, and patient-relevant model development. The challenge is that the assay landscape is broad. Viability, reporter gene, high-content imaging, primary cell, co-culture, organoid, and immune-cell assays each answer different questions and introduce different technical risks. Practical assay selection depends on biological relevance, throughput, robustness, endpoint sensitivity, and the decision that the data must support. This article explores the major cell-based assay formats and provides a practical guide for selecting the right approach in drug discovery workflows.
The main types of cell-based assays in drug discovery
Cell-based assay selection usually starts with the biological question rather than the assay technology. Different formats measure different layers of cellular behavior, from simple viability changes to pathway-specific signaling, disease-relevant function, and image-derived phenotypes. The main types of cell-based assays often overlap in discovery workflows, but each category has a distinct role in screening, hit confirmation, mechanism-of-action work, and translational model development.
Cell viability and cytotoxicity assays
In cell-based assays for drug discovery, viability and cytotoxicity testing usually comes quite early. Before spending time on more detailed biology, researchers need to know how the cells are handling the compound. A response may look promising at first, but if the same compound is also reducing cell health, the result may be linked to general stress rather than a clean target effect.
These assays are also useful because they can be run across different dose levels, exposure times, cell lines, and treatment conditions. This makes them a practical starting point in many in vitro assays in drug discovery programmes, especially when a team needs to compare several compounds quickly.
MTT is one of the older and more familiar types of cell-based assays used for basic viability work. It looks at metabolic activity by measuring the reduction of tetrazolium salts by active cells. The readout can give a useful picture of cell health, but it is not always simple. Changes in mitochondrial activity, shifts in metabolism, or interference from the test compound can all affect the final signal.
CellTiter-Glo is commonly used in larger plate-based screens where many samples or dose points have to be checked side by side. The assay reads ATP levels, so it gives a practical indication of how many cells are still metabolically active after treatment. It is especially helpful when several compounds or conditions need to be compared without making the workflow too complicated.
LDH release assays are used for a different type of readout. They look for lactate dehydrogenase in the culture medium, which usually appears there when the cell membrane has been damaged. Because of that, LDH is a good option when the question is whether a compound is causing membrane damage, cytotoxicity, or broader cell injury.
Together, these assays help researchers make early decisions during compound triage, safety profiling, and off-target liability assessment. They do not prove mechanism of action by themselves, but they can show whether a compound is worth taking forward into functional assays, phenotypic assay drug discovery studies, imaging-based readouts, or primary cell assays.
Reporter gene assays
Reporter gene assays convert pathway activity into a measurable optical or secreted signal. Luciferase reporters are widely used because they produce a strong signal and are sensitive enough for many pathway-based assays. GFP reporters are useful when live-cell imaging or microscopy-based readouts are needed, but the signal can take time to mature, and background fluorescence may affect sensitivity. SEAP-based reporters work differently because the alkaline phosphatase signal is released into the culture medium. This allows researchers to sample the medium without lysing the cells, which can be useful when the same culture needs to be followed over time.Reporter assays are especially useful for pathway activation, transcription factor activity, GPCR signaling, and nuclear receptor biology. They are often selected when a defined promoter, response element, or signaling node can be linked to the drug target or disease mechanism. A well-designed reporter assay can support screening, counter-screening, agonist or antagonist profiling, and structure-activity relationship decisions. The main risk is biological oversimplification. Reporter constructs may not fully reproduce endogenous regulation, chromatin context, receptor expression, or pathway feedback. Orthogonal confirmation with endogenous markers is usually needed before reporter activity is treated as definitive biology. For broader assay selection principles, our blog ‘Choosing the right assay for drug discovery‘Â can support early planning.
Functional and phenotypic assays
Functional and phenotypic assays measure cellular behaviour closer to disease biology. Rather than focusing only on whether a pathway is activated, they assess whether cells change in a way that is biologically meaningful. Common examples include migration, invasion, apoptosis, differentiation, immune activation, cytokine release, phagocytosis, chemotaxis, and changes in cell morphology or barrier function.
These assays are useful across many discovery areas because they can capture disease-relevant responses that simpler pathway readouts may miss. In oncology, fibrosis, inflammation, and wound-healing models, migration and invasion assays can show whether treatment affects cell movement or tissue-remodelling behaviour. Apoptosis assays can help determine whether cells are entering programmed cell death, using readouts such as caspase activation, phosphatidylserine exposure, mitochondrial disruption, or DNA fragmentation. Immune-related assays may measure T-cell activation, cytokine secretion, macrophage polarisation, immune-cell killing, or changes in surface marker expression.
Differentiation assays are also important when the question is whether cells are acquiring a mature or disease-relevant state, rather than only whether their growth has slowed. This can be relevant in stem cell models, immune-cell systems, regenerative medicine, metabolic disease, and other settings where lineage markers and functional maturity matter.
These assays are most useful when disease-relevant phenotypic readouts matter more than isolated pathway activity. They can also support target deconvolution and mechanism-of-action characterization when the molecular target is unknown or only partially validated. Assay design should define the phenotype carefully, because migration, invasion, apoptosis, immune activation, and differentiation can all be influenced by proliferation, media composition, matrix conditions, donor variability, cell passage number, and treatment timing.
Imaging-based and high-content assays
Imaging-based and high-content assays use automated microscopy to measure cellular responses at single-cell or subcellular resolution. These platforms can quantify morphology, organelle structure, protein localization, cytoskeletal organization, cell cycle state, nuclear changes, and marker expression across thousands to millions of cells. Multiparametric imaging is valuable because it captures several biological features in the same experiment rather than reducing the response to one bulk signal.
High-content formats are well suited to spatially resolved biology, subcellular localization, and morphological profiling. They are also useful when compounds produce heterogeneous effects across a cell population. The trade-off is operational complexity. Image quality, segmentation accuracy, staining consistency, plate effects, and data analysis pipelines can strongly influence results. For teams developing imaging or broader cellular workflows, our blog ‘Discovery Studio cellular and molecular wetlab page‘Â can provide a practical starting point.
Biochemical assays vs. cell-based assays: when to use which
The biochemical vs cell-based assays decision depends on how much biological context is needed to answer the discovery question. Biochemical assays work best when the target is already known and the study needs a direct measurement, such as binding, inhibition, activation, or enzyme kinetics. Because the experiment is run under controlled conditions, these assays are generally quicker, easier to scale, and less affected by the variability that can appear in cell-based assay formats. They also make it easier to understand whether a compound is acting on the target as expected. For purified enzymes, receptor binding studies, protein interactions, or early structure-activity relationship work, biochemical formats can provide a clean view of compound potency against the intended target.
Cell-based assays become more useful when target activity depends on cellular uptake, pathway wiring, protein localization, receptor trafficking, metabolic state, or disease-relevant phenotype. They also introduce early signals related to permeability, efflux, metabolism, cytotoxicity, and broader ADME-linked behavior. This added complexity can reduce throughput, but it improves translational relevance when the cellular model is well chosen.
A strong discovery cascade often uses both. Biochemical assays can confirm direct target modulation, while cell-based assays test whether that modulation produces the expected biological response in a relevant system. Assay strategy should be matched to program stage, biology, and decision risk.
Choosing the right cell model: cell lines, primary cells and iPSC-derived models
Cell model selection should be tied to the decision the assay must support. Established immortalized cell lines are often the practical starting point for early screening, assay optimization, and concentration-response profiling. They are accessible, scalable, easier to standardize, and usually compatible with automation. Their limitations are also well known. Long-term culture, genetic drift, altered signaling, and nonphysiologic expression patterns can weaken disease relevance, especially when the biology depends on native cell state or tissue context.
Primary cell assays provide a closer link to human biology, particularly in immunology, inflammation, fibrosis, oncology, and metabolic disease. Primary cells can preserve donor-specific responses, native receptor expression, and disease-associated behavior that may be absent in transformed lines. The trade-off is variability. Donor differences, limited cell availability, passage sensitivity, isolation method, and culture conditions can affect assay robustness. For that reason, primary cells are often introduced after early assay feasibility is established, or when translational relevance is critical from the beginning.
iPSC-derived models sit between scalability and human relevance. They are valuable for CNS, cardiac, skeletal muscle, retinal, and rare disease programs where access to relevant primary tissue is limited. Patient-derived or gene-edited iPSC models can be useful for disease modelling, phenotypic screening, and safety testing. However, they need careful handling because maturation state, batch-to-batch variation, and consistency can all affect the results.
In practice, the choice of model depends on the stage of the programme, the target biology, the complexity of the endpoint, the required throughput, and how much variability is acceptable. For early screening, robust cell lines are often the most practical option. When a programme moves into hit validation or translational work, primary cells or iPSC-derived models can give a closer link to the biology being studied.
Key quality parameters for a robust cell-based assay
A good cell-based assay needs to give a clear biological response, but that response also has to be consistent. It should not work well on one plate and then shift on the next. During assay development, researchers usually look at the assay window to see whether the positive and negative controls are separated enough to support reliable decisions. The Z-factor is often used for this because it considers both the size of the signal and the variation in the data.
Signal-to-background ratio is also useful, but it should not be judged on its own. A strong signal can still be misleading if the data are noisy or if replicate values move too much between runs. In that situation, compounds may appear more or less potent than they really are, which can affect ranking and follow-up decisions.
Reproducibility depends on many small details in the workflow. Assay performance can shift because of several practical factors, including how many cells are seeded, how long they are incubated, how reagents are prepared, edge effects on the plate, media conditions, and the timing of detection. Cell passage number also needs attention. If cells are kept in culture for too many passages, their growth rate, receptor expression, pathway activity, or drug response may change. That is why passage limits should be defined during assay development and followed during routine testing.
Controls are needed to make the assay results meaningful. A positive control confirms that the assay is able to produce the expected response. Negative and vehicle controls set the baseline and help show whether any change is coming from the compound itself, the solvent, or other assay-related interference. Tracking control performance over time can also show when an assay is starting to drift, before the data become unreliable. Check out our blog ‘Common pitfalls in assay development and how to avoid them‘.
Cell-based assay development at Discovery Studio
Discovery Studio develops custom cell-based assays from the first assay idea through optimisation, validation, and data generation. The work starts with the biology: what the assay needs to show, which cell model is most relevant, and which endpoint will give useful results for the programme.
Depending on the target and disease area, assay development may include viability assays, reporter systems, functional readouts, immune-cell assays, primary cell models, or imaging-based formats. When one endpoint is not enough to understand compound behaviour, multiparametric readouts can be added to give a broader view of the response.
MSD-based detection can also be built into the workflow for sensitive cytokine, signalling, or biomarker measurement, learn more via our MSD assay development guide. Through its cellular and molecular wet lab capabilities, Discovery Studio helps connect in vitro assay systems with more translational decision-making.
Search all newsposts
Popular Posts
Tags
Get in touch with us
Frequently asked questions about cell-based assays for drug discovery
What are cell-based assays used for in drug discovery?
Cell-based assays help scientists see how a compound behaves inside living cells. Unlike basic biochemical tests they show what actually happens in a real cellular environment. In drug discovery these assays are used for early screening comparing how strong compounds are checking toxicity and safety studying biological pathways understanding how a compound works and building models that better reflect real disease conditions.
What is a phenotypic assay and how is it different from a target-based assay?
A phenotypic assay measures a change in cell behaviour. This could be migration, apoptosis, differentiation, immune activation, or a visible change in cell shape. In phenotypic assay drug discovery, the focus is often on the disease-relevant response first, even when the exact target is not fully understood. A target-based assay starts from the opposite direction. It is built around a known protein, receptor, enzyme, or pathway.
How do primary cells differ from cell lines in drug discovery assays?
Primary cells come directly from donor tissue or blood so they tend to reflect human biology more closely. They are often preferred when disease relevance or translational accuracy is important. Cell lines are easier to grow maintain and reuse across experiments which makes them very useful for screening studies. The downside is that long cultured cell lines do not always behave like normal cells. Over time signaling receptor expression growth patterns and overall cell behavior can change.
What is a multiparametric cell-based assay?
A multiparametric cell-based assay measures several different responses in the same experiment. Instead of measuring only one thing like cell viability or a single pathway signal researcher can look at several changes at the same time such as cytokine release marker expression cell shape protein location and pathway activation. This gives a fuller picture of how a compound is affecting the cell especially when one measurement alone is not enough.
When should high-content imaging be used instead of a plate-reader assay?
High-content imaging is useful when the position, shape, or pattern of the response matters. It can show where a signal appears inside the cell, whether cell morphology has changed, how responses differ from cell to cell, or whether organelles are affected. A plate-reader assay is usually better when the biological question can be answered with one overall signal from each well.
How many compounds can a cell-based assay screen in a typical campaign?
There is no single number because it depends on the assay format, endpoint, automation, and cell model. Simple homogeneous assays can be scaled for large compound libraries. More complex work, such as primary cell assays, high-content imaging, or detailed phenotypic assays, is usually run on smaller focused libraries because the setup, handling, and analysis take more time.